Immune signalling encompasses many diverse processes, including responses to antigens and to cytokines such as interleukins and interferons. These signalling pathways are generally initiated by the activation of protein tyrosine kinases and lead to the involvement of multiple intracellular signalling cascades, including activation of the Ras-mitogen-activated protein (MAP) kinase pathway and activation of phosphatidylinositol 3-kinase (PI 3-kinase), which itself couples to a range of signalling pathways.
A common feature in intracellular signalling pathways is the assembly of multi-protein complexes involving extensive protein-protein interactions. These associations can be directed by a number of protein interaction domains, including Src homology 2 (SH2) domains, which bind phosphotyrosine residues, and SH3 domains, which bind proline-rich regions, amongst others. The recent characterisation of a new adaptor protein -termed Grb-2-associated binder 2 (Gab2) -that binds to the cytoplasmic protein tyrosine phosphatase SHP-2 adds to the evergrowing family of scaffolding or docking proteins that are involved in immune signalling [1] . Other important examples of these docking proteins include the cytosolic Vav protein and the membrane-localised linker for activated T cells (LAT). These proteins serve not only as a nucleation point for the regulated assembly of multiprotein complexes but may also be involved in targeting the entire complex to a particular subcellular location, for example pleckstrin homology (PH) domains can target proteins for membrane localisation.
An intriguing finding is that SHP-2 is often found in these signalling complexes. This enzyme was cloned and identified only six years ago and has since been implicated in many different signalling pathways, including those initiated by stimulation with growth hormone or insulin, or by triggering of the T-cell receptor or cytokine receptors [2] . SHP-2 and the related enzyme SHP-1 are unique amongst tyrosine phosphatases as they have two tandem SH2 domains. Besides serving to target SHP-2 to various tyrosine-phosphorylated proteins, these SH2 domains also regulate the activity of SHP-2. In the unbound state, SHP-2 adopts a 'closed' conformation in which the aminoterminal SH2 domain interacts extensively with the phosphatase domain, blocking the active site. Upon binding of the SH2 domains to a tyrosine-phosphorylated target, the enzyme adopts an 'open', active conformation [3] . Thus, the SH2 domains not only direct SHP-2 to the correct intracellular location but also repress the catalytic activity until SHP-2 is localised to an appropriate protein complex. SHP-2 is required for the activation of the Ras-MAP kinase cascade, because the expression of a catalytically inactive, dominant-interfering form of SHP-2 inhibits MAP kinase activation in response to various signals [2] . SHP-2 function is also required for activation of cytokine-induced immediate-early gene expression. The precise point(s) at which SHP-2 acts in signalling pathways, however, is unclear. Several reports have placed SHP-2 upstream of MAP kinase, and perhaps even upstream of Ras. Studies in the fruit fly Drosophila melanogaster suggest, however, that SHP-2 function is not that simple. Corkscrew (Csw), the Drosophila homologue of SHP-2, regulates the Sevenless signalling pathway, which triggers differentiation of the R7 photoreceptor cell in the compound eye. Genetic experiments have revealed the complexity of SHP-2 action, showing that Csw acts either parallel to or both upstream and downstream of Ras in the Sevenless pathway [4] . The docking protein Dos (for daughter of Sevenless) is a binding target and putative substrate for Csw and is required for the signalling roles of Csw [5, 6] .
By analogy to the Drosophila Sevenless signalling pathway, SHP-2 signalling in immune cells was predicted to involve a Dos homologue. Indeed, a common feature in immune signalling pathways is the association of SHP-2 with a tyrosine-phosphorylated cytosolic docking protein of 95-110 kDa, which also forms a complex with various other signalling proteins such as the adaptor proteins Grb2 and Shc, and the p85 regulatory subunit of PI 3-kinase [7] . The recent purification and cloning of this ~95-110 kDa docking protein [1] have in fact revealed that it has only limited homology to Dos, restricted to the PH domain, but greater similarity to Gab1, a mammalian adaptor protein involved in diverse receptor signalling pathways, as shown in Figure 1 : for this reason, it has been christened Gab2. The amino-acid identity outside the PH domain is only 30% between Gab1 and Gab2; the relative positions of potential tyrosine phosphorylation sites, proline-rich domains, and the c-Met-binding domain (a region in Gab1 that binds to the c-Met receptor) are conserved, however, consistent with the proposed roles for these proteins as assembly points for multi-protein complexes ( [1] ; Figure 1 ).
Initial studies of Gab2 in cytokine signalling, carried out in BaF3 cells (interleukin-3 (IL-3)-dependent haemopoietic cells), have provided some surprising insights into the role of SHP-2. Gu et al. [1] mapped the binding sites of the SH2 domains of SHP-2 to tyrosines 604 and 633 of Gab2: truncating the carboxy-terminal residues from tyrosine 604 onwards (∆Y2 Gab2), or mutating tyrosines 604 and 633 to phenylalanine (Y2F Gab2), resulted in forms of Gab2 that were unable to bind SHP-2. The associations of Gab2 with other signalling proteins, such as Shc, Grb2, and p85, were unaffected by these alterations. Expression of the ∆Y2 or Y2F versions of Gab2 inhibited IL-3-induced immediate-early gene expression, showing that SHP-2 association with Gab2 is required for the mediation of these signals. MAP kinase activation is unexpectedly potentiated in these experiments, however, suggesting that SHP-2 is acting in a pathway either parallel to or downstream of MAP kinase to regulate gene expression. The potentiation of MAP kinase activity by the ∆Y2 or Y2F forms of Gab2 could be explained by stimulation of the Ras-MAP kinase pathway resulting from PI 3-kinase activation, as the PI 3-kinase p85 subunit binding sites on Gab2 are unaffected by the mutations (an interpretation consistent with some recent studies of Gab1 -see [8] ). Interestingly, expression of dominant-negative SHP-2 inhibits both induction of immediate-early gene expression and activation of MAP kinase [1] , demonstrating that SHP-2 acts in at least two distinct places in the signalling pathways.
But where exactly does SHP-2 act in cytokine signalling? Figure 2 illustrates some of the possibilities. The function of SHP-2 in regulating gene expression clearly requires Gab2 (Figure 2, arrow d) . The role of SHP-2 in activating MAP kinase, however, may or may not be Gab2 dependent. Only about 10% of total cellular SHP-2 appears to be associated with Gab2 in IL-2-stimulated BaF3 cells, and other SHP-2-associated proteins have been observed, suggesting that SHP-2 may act through a Gab2-independent pathway to activate MAP kinase ( Figure 2 , arrow a) [1] . Alternatively, cytokine-induced MAP kinase activation could be mediated by the dual actions of PI 3-kinase and SHP-2 both acting through Gab2 (Figure 2, arrows b,c) . In this scenario, overexpression of mutated forms of Gab2 that do not bind SHP-2 could potentiate MAP kinase activation through increased PI 3-kinase activity, thereby overcoming the loss of the SHP-2 contribution. Expression of a mutated form of Gab2 in which the binding sites for both SHP-2 and p85 were abolished would address this question: if the regulation of MAP kinase by SHP-2 were Gab2 independent, then expression of dominant-negative SHP-2 in combination with the form of Gab2 lacking the binding sites for both SHP-2 and p85 would be predicted to inhibit MAP kinase activation.
Although the identification of Gab2 has clarified the role of SHP-2 in immune signalling, many questions remain unanswered. In particular, the substrate(s) for SHP-2 has yet to be identified. Gab2/Dos has been proposed as a substrate because of its association with 'substrate-trapping' mutants (catalytically inactive mutants that still bind substrates) of SHP-2/Csw [5, 9] and because of its dephosphorylation by SHP-2 following stimulation of BaF3 cells [9, 10] . Overexpression of catalytically inactive SHP-2 results in the hyperphosphorylation of Gab2, consistent with Gab2 being a SHP-2 substrate [9] . Mutating the SHP-2-binding sites of Gab2 does not result in increased IL-3-stimulated Gab2 phosphorylation [1] , however, as one might expect if Gab2 were a SHP-2 substrate because, in this context, SHP-2 would not be recruited to Gab2, a step that might also be necessary for SHP-2 activation. A problem in interpreting this experiment, however, is that the loss of the two phosphorylation sites in Gab2 that are required for SHP-2 binding might mask increased phosphorylation at other sites. Interestingly, we found that expression of catalytically inactive SHP-2 in activated T cells results in the hyperphosphorylation of three proteins: Gab2, LAT and an unidentified p52 protein, all potential targets for SHP-2 [11] . These hyperphosphorylation events were only observed in the membrane fraction, so the subcellular localisation of multimeric complexes is clearly critical.
How is the subcellular targeting of Gab2 regulated? The presence of a PH domain in Gab2 suggests that this adaptor protein is targeted to the membrane; indeed, after IL-3 stimulation of BaF3 cells, a small amount of Gab2 was found associated with SHP-2 and PI 3-kinase in the membrane fraction [10] . Similarly, in Jurkat T cells a small amount of a Gab2-SHP-2 complex was found at the membrane after stimulation; expression of catalytically inactive SHP-2 significantly increased membrane targeting [11] . If the membrane-localised LAT protein is a target for SHP-2 activity, then this increase in membrane targeting could be explained by binding of SHP-2 to LAT via the inactive catalytic domain of SHP-2. Alternatively, LAT may play a direct role in targeting the Gab2-SHP-2 complex to the membrane.
How SHP-2 is involved in coupling signals to the MAP kinase pathway and to regulation of immediate-early gene expression is still unclear. As SHP-2 has a positive effect on coupling of receptors to MAP kinase, its key substrate(s) is presumably a negative regulator of this pathway. As indicated above, experiments need to be carried out to determine whether MAP kinase regulation by SHP-2 is dependent or independent of Gab2. Several other SHP-2-binding proteins have been identified, including the SHPS-1/SIRP family of inhibitory receptor proteins and a 135 kDa SHP-2-associated protein [9] that may be involved in the Gab2-independent actions of SHP-2. Regulation of immediate-early gene expression by the Gab2-SHP-2 complex may occur at a point downstream of MAP kinase activation, or alternatively via a parallel pathway (Figure 2, arrow d) . The cloning of Gab2 adds to the numerous ports of call identified for SHP-2; now the challenge lies in mapping the course that SHP-2 navigates through the many different intracellular signalling cascades.
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Figure 2
Involvement of SHP-2 in IL-3 signalling. Binding of IL-3 to its receptor leads to activation of Janus kinases (JAK) and tyrosine phosphorylation of the adaptor protein Gab2. The signalling pathways downstream of Gab2 are identified by four arrows (a-d); see text for details. Each pathway ultimately leads to expression of immediate-early genes, for example c-fos. Binding sites on Gab2 are marked as Y* for phosphotyrosine and PXXP for proline-rich regions. Note that the motifs for association of proteins with Gab2 have been experimentally defined only for SHP-2. Besides associating with Gab2, SHP-2 may also associate with an unknown adaptor protein marked as ?. 
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